<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03992846</url>
  </required_header>
  <id_info>
    <org_study_id>18-OBE2109-003</org_study_id>
    <nct_id>NCT03992846</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Study to Assess the Efficacy and Safety of Linzagolix in Subjects With Moderate to Severe Endometriosis-associated Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the efficacy and safety of linzagolix
      administered orally once daily for 3 months at a dose of 75 mg alone or of 200 mg in
      combination with add-back hormone replacement therapy (ABT: estradiol (E2) 1 mg /
      norethisterone acetate (NETA) 0.5 mg) versus placebo, in the management of moderate to severe
      endometriosis-associated pain (EAP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled study to demonstrate the
      efficacy and safety of linzagolix administered orally once daily at doses of 75 mg alone and
      200 mg in combination with low dose ABT (E2 1 mg/NETA 0.5 mg) versus placebo in the
      management of moderate to severe EAP in 450 women.

      Eligible subjects who have completed the 6-month treatment period may enter a separate
      extension study for 6 additional months of active treatment (no placebo control). Subjects
      who do not continue in the extension study will enter a 6 month treatment-free follow-up
      phase.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change at Month 3 from baseline in the mean daily assessment of dysmenorrhea measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 3</time_frame>
    <description>Change at Month 3 from baseline in the mean daily assessment of non-menstrual pelvic pain measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in dysmenorrhea measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in non-menstrual pelvic pain measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyschezia</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in dyschezia measured on a 0-10 Numeric Rating Scale (NRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Pelvic Pain</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in overall pelvic pain measured on a 0-10 Numeric Rating Scale (NRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference of pain with the ability to perform daily activities</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in the interference of pain with the ability to perform daily activities, measured using the pain dimension of the Endometriosis Health Profile-30 (EHP-30) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia</measure>
    <time_frame>Baseline to Month 6</time_frame>
    <description>Change from baseline to Month 6 in dyspareunia measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No analgesic use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at Month 6</time_frame>
    <description>Proportion of subjects reporting no analgesic use for endometriosis associated pain, during the preceding 4-week period at Month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No opiate use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at Month 6</time_frame>
    <description>Proportion of subjects reporting no opiate use for endometriosis associated pain, during the preceding 4-week period at Month 6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add-back capsule (E2 1 mg / NETA 0.5 mg)</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule to match Add-back capsule</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subject must have:

          -  Her most recent surgical and - if available - histological diagnosis of pelvic
             endometriosis up to 10 years before screening.

          -  Moderate to severe endometriosis-associated pain during the screening period.

          -  Regular menstrual cycles.

          -  BMI ≥ 18 kg/m2 at the screening visit. -

        Exclusion Criteria:

        The subject will be excluded if she:

          -  Is pregnant or breast feeding or is planning a pregnancy within the duration of the
             treatment period of the study.

          -  Is less than 6 months postpartum or 3 months postabortion/ miscarriage at the time of
             entry into the screening period.

          -  Has had a surgical history of any major abdominal surgery within 6 months or any
             interventional surgery for endometriosis performed within a period of 2 months before
             screening.

          -  Did not respond to prior treatment with GnRH agonists or GnRH antagonists for
             endometriosis.

          -  Has a history of, or known, osteoporosis or other metabolic bone disease.

          -  Has chronic pelvic pain that is not caused by endometriosis and requires chronic
             analgesic or other chronic therapy which would interfere with the assessment of
             endometriosis-associated pain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females Only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>+41 22 552 38 40</phone>
    <email>clinicaltrials@obseva.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Achieve Clinical Research/ ID # 601</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Choice Research, LLC/ ID # 609</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research/ ID # 618</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universal Axon - Homestead, LLC/ ID # 620</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc./ ID # 625</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wellington Anti-Aging, LLC/ ID # 613</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quad Clinical Research LLC/ ID # 616</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials/ ID # 612</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced Specialty Research/ ID # 610</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83687</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affinity Clinical Research Institute/ ID # 622</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center for Women's Research/ ID # 619</name>
      <address>
        <city>Palos Heights</city>
        <state>Illinois</state>
        <zip>60463</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Women's &amp; Family Care, LLC dba GTC Research/ ID # 608</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research / ID # 611</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quad Clinical Research LLC/ ID # 615</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Women's Health &amp; Wellnes/ ID # 603</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington/ ID # 614</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28412</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UWCR - Lyndhurst Clinical Researc/ ID# 605</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Associates, Inc./ ID# 606</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center/ ID # 604</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Invocare Medical Research &amp; Healthcare Center/ ID # 607</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research LLC/ ID# 602</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Next Innovative Clinical Research/ ID # 617</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brownstone Clinical Trials/ ID # 621</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Storks Research, LLC/ ID # 623</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic/ ID # 624</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tyrol clinics/ ID # 104</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kepler University Hospital GmbH / ID # 102</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salzburger Landeskliniken / ID # 105</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Vienna University of Medicine Vienna / ID # 101</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AKH Vienna University of Medicine Vienna/ ID # 103</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Avis-Medica/ ID # 134</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sliven/ ID # 131</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Centre Excelsior /ID # 135</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Group Practice for Specialized Medical Assistance in GINART/ ID # 132</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment St. Sofia/ ID # 137</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Doverie / ID # 136</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sofiamed&quot;/ ID # 133</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gyneko spol.s r.o./ ID # 164</name>
      <address>
        <city>Karolinka</city>
        <zip>75605</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>G-CENTRUM Olomouc s.r.o./ ID # 161</name>
      <address>
        <city>Olomouc</city>
        <zip>77200</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MUDr Jan Drahonovsky, Ustav pro peci o matku a dite/ ID #163</name>
      <address>
        <city>Praha 4</city>
        <zip>14700</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynekologicko - Porodnicka Ambulance/ ID # 162</name>
      <address>
        <city>Tábor</city>
        <zip>39003</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gynekologie MU Dr.Lubomir Mikulasek / ID # 160</name>
      <address>
        <city>Ujezd nad Lesy</city>
        <zip>19016</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Besançon Hopital/ ID # 204</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estaing/ ID # 202</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles/ ID # 201</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Carémeau/ ID # 203</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Strasbourg - Hopital Hautepierre/ ID # 205</name>
      <address>
        <city>Strasbourg</city>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur / ID # 206</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Principal SMO Kft/ ID # 250</name>
      <address>
        <city>Baja</city>
        <state>Bacs-Kiskun</state>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Róbert Károly Magánkórház/ ID # 253</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szent Anna Szuleszeti-Nogyogyaszati/ ID # 251</name>
      <address>
        <city>Debrecen</city>
        <zip>4024</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mediroyal Prevencios Kozpont/ ID # 252</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Kozponti Korhaz/ ID # 254</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ / ID # 255</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne/ ID # 402</name>
      <address>
        <city>Świdnik</city>
        <state>Lubelskie</state>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prywatna Klinika Ginekologiczno - Położnicza/ ID # 404</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-224</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VITA LONGA Sp. z o.o./ ID # 408</name>
      <address>
        <city>Katowice</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Research sp. Z o. O/ ID # 406</name>
      <address>
        <city>Katowice</city>
        <zip>40-001</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Krzysztof Wilk/ ID # 411</name>
      <address>
        <city>Katowice</city>
        <zip>40-301</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zrowotnej GynCentrum/ ID # 407</name>
      <address>
        <city>Katowice</city>
        <zip>40-851</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Maciej Żymła/ ID # 412</name>
      <address>
        <city>Knurów</city>
        <zip>44-190</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kotarski Jan Specjalistyczny Gabinet Ginekologiczno Polozniczy/ ID # 405</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Chodźki Lublin/ ID # 403</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum Ginekologii Endokrynologii i Medycyny Rozrodu &quot;Artemida&quot;/ ID # 409</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu/ ID # 410</name>
      <address>
        <city>Przemyśl</city>
        <zip>37-700</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Lekarski Krzysztof Dynowski / ID # 401</name>
      <address>
        <city>Warsaw</city>
        <zip>02-929</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quantum Medical Center SRL/ ID # 353</name>
      <address>
        <city>Bucharest</city>
        <zip>12071</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic &quot;Nicolae Malaxa&quot;/ ID # 352</name>
      <address>
        <city>Bucharest</city>
        <zip>22448</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrul Medical EUROMED/ ID # 351</name>
      <address>
        <city>Bucuresti</city>
        <zip>20764</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sp Cl de Obstetrica si Ginecologie &quot;Prof. Dr. Panait Sirbu&quot;/ ID # 354</name>
      <address>
        <city>Bucuresti</city>
        <zip>60251</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gine Plus SRL Cluj- Napoca/ ID # 357</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400698</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Oradea/ ID # 356</name>
      <address>
        <city>Oradea</city>
        <zip>410053</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrul Medical GALENUS/ ID # 355</name>
      <address>
        <city>Târgu-Mureş</city>
        <zip>540236</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dexeus/ ID # 306</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica IVI Bilbao/ ID # 305</name>
      <address>
        <city>Leioa</city>
        <zip>39004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz/ ID # 301</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Reina Sofia/ ID # 304</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga/ ID # 303</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Consorci Hospital General Universitari Valencia/ ID # 302</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City clinical maternity hospital №1/ ID # 502</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58003</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk regional perinatal center, Family planning center/ ID # 506</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Maternity Hospital #6/ ID # 504</name>
      <address>
        <city>Kyiv</city>
        <zip>02125</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical center of LLC &quot;Medical Center &quot;Verum&quot;/ ID # 503</name>
      <address>
        <city>Kyiv</city>
        <zip>03039</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Pediatrics Obstetrics and Gynecology/ ID # 508</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Clinical Hospital #9/ ID # 501</name>
      <address>
        <city>Kyiv</city>
        <zip>04112</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyiv City Center of Reproductive and Perinatal Medicine/ ID # 509</name>
      <address>
        <city>Kyiv</city>
        <zip>04210</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ternopil' Communal City Hospital #2/ ID # 511</name>
      <address>
        <city>Ternopil</city>
        <zip>46400</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vinnytsia City Clinical Hospital &quot;Center of Mother and the Child &quot;/ ID # 510</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21019</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zaporizhzhya Regional Clinical Hospital/ ID # 505</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternity Hospital № 3/ ID # 507</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69071</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Investigator</last_name>
      <email>clinicaltrials@obseva.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Bulgaria</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Dyschezia</keyword>
  <keyword>Non-menstrual pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

